Therapeutic Apheresis and Dialysis

Papers
(The H4-Index of Therapeutic Apheresis and Dialysis is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
COVID‐19 of dialysis patients in Japan: Current status and guidance on preventive measures47
The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis29
Double filtration plasmapheresis: Review of current clinical applications27
Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan18
The scientific basis and future of lipoprotein apheresis17
Assessment of the accuracy of an intermittent‐scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (AIDT2H) study15
Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications15
A COVID‐19 pandemic‐specific, structured care process for peritoneal dialysis patients facilitated by telemedicine: Therapy continuity, prevention, and complications management14
Application of plasmapheresis for Covid‐19 patients13
Effectiveness of SARS‐CoV‐2 vaccines on hemodialysis patients in Japan: A nationwide cohort study13
Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: A meta‐analysis of randomized controlled trials13
Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically‐ill COVID‐19 patients13
Potential limitations of plasmapheresis in treatment of COVID‐19 patients: How to overcome them?12
Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long an12
Renal replacement therapy for critically ill patients with COVID‐19‐associated acute kidney injury: A review of current knowledge12
0.05031681060791